Novo Nordisk’s Once-Weekly Insulin Gains Superiority Finding As Lilly Advances

 
• By Alaric DeArment

The ONWARDS 1 and 6 results closely follow success in ONWARDS 2 in April, further helping strengthen insulin icodec’s potential market position, but Lilly is nipping at Novo’s heels.

Novo Nordisk announced data from the ONWARDS 1 and 6 trials of insulin icodec • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas